Use of subcutaneous implantable infusion systems in neoplastic and AIDS patients requiring long term venous access

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Objective: To evaluate the life span and complication rates of totally implantable infusion devices in patients with short bowel syndrome and in immunocompromised patients with AIDS, lymphoma, and myeloma who required long term central venous access. Design: Prospective open study. Setting: University hospital, Italy. Subjects: Group I - 5 patients with short bowel syndrome; group II - 11 patients with AIDS; and group III - 15 patients with lymphoma or multiple myeloma (1 of whom had 2 devices implanted). Main outcome measures: Duration of implantation and incidence of catheter-related complications. Results: The mean duration/patient of the catheter was 422 days (range 28-1257) in group I; 104 days (range 43-262) in group II; and 415 days (range 62-1280) in group III. There were no catheter related complications in the patients in group I (short bowel syndrome). Of the 11 patients with AIDS (group II) 4 developed catheter related infections (0.32/100 catheter days), and 1 developed a thrombotic occlusion. All 5 catheters were removed (3 for infection). Of the 15 patients with lymphoma or myeloma who had 16 catheters implanted (group III), 1 patient developed 3 infective episodes (0.05/100 catheter days), 1 catheter migrated and 1 occluded. All 3 catheters were removed. Conclusion: Totally implantable infusion systems can safely be used for prolonged periods in immunocompromised patients, including those with AIDS if their life expectancy is reasonable.

Original languageEnglish
Pages (from-to)137-142
Number of pages6
JournalEuropean Journal of Surgery, Acta Chirurgica
Volume161
Issue number2
Publication statusPublished - 1995

Fingerprint

Subcutaneous Infusions
Acquired Immunodeficiency Syndrome
Catheters
Short Bowel Syndrome
Lymphoma
Immunocompromised Host
Catheter-Related Infections
Equipment and Supplies
Life Expectancy
Multiple Myeloma
Italy
Outcome Assessment (Health Care)
Prospective Studies

Keywords

  • AIDS patients
  • cancer patients
  • catheter related complications
  • infusion ports

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{dc9d77fcf3dc49899f0c1fe5d7d5ecbc,
title = "Use of subcutaneous implantable infusion systems in neoplastic and AIDS patients requiring long term venous access",
abstract = "Objective: To evaluate the life span and complication rates of totally implantable infusion devices in patients with short bowel syndrome and in immunocompromised patients with AIDS, lymphoma, and myeloma who required long term central venous access. Design: Prospective open study. Setting: University hospital, Italy. Subjects: Group I - 5 patients with short bowel syndrome; group II - 11 patients with AIDS; and group III - 15 patients with lymphoma or multiple myeloma (1 of whom had 2 devices implanted). Main outcome measures: Duration of implantation and incidence of catheter-related complications. Results: The mean duration/patient of the catheter was 422 days (range 28-1257) in group I; 104 days (range 43-262) in group II; and 415 days (range 62-1280) in group III. There were no catheter related complications in the patients in group I (short bowel syndrome). Of the 11 patients with AIDS (group II) 4 developed catheter related infections (0.32/100 catheter days), and 1 developed a thrombotic occlusion. All 5 catheters were removed (3 for infection). Of the 15 patients with lymphoma or myeloma who had 16 catheters implanted (group III), 1 patient developed 3 infective episodes (0.05/100 catheter days), 1 catheter migrated and 1 occluded. All 3 catheters were removed. Conclusion: Totally implantable infusion systems can safely be used for prolonged periods in immunocompromised patients, including those with AIDS if their life expectancy is reasonable.",
keywords = "AIDS patients, cancer patients, catheter related complications, infusion ports",
author = "P. Dionigi and T. Cebrelli and V. Jemos and L. Minoli and P. Gobbi and G. Dimitrov",
year = "1995",
language = "English",
volume = "161",
pages = "137--142",
journal = "European Journal of Surgery, Acta Chirurgica",
issn = "1102-4151",
publisher = "Oslo Scandinavian University Press",
number = "2",

}

TY - JOUR

T1 - Use of subcutaneous implantable infusion systems in neoplastic and AIDS patients requiring long term venous access

AU - Dionigi, P.

AU - Cebrelli, T.

AU - Jemos, V.

AU - Minoli, L.

AU - Gobbi, P.

AU - Dimitrov, G.

PY - 1995

Y1 - 1995

N2 - Objective: To evaluate the life span and complication rates of totally implantable infusion devices in patients with short bowel syndrome and in immunocompromised patients with AIDS, lymphoma, and myeloma who required long term central venous access. Design: Prospective open study. Setting: University hospital, Italy. Subjects: Group I - 5 patients with short bowel syndrome; group II - 11 patients with AIDS; and group III - 15 patients with lymphoma or multiple myeloma (1 of whom had 2 devices implanted). Main outcome measures: Duration of implantation and incidence of catheter-related complications. Results: The mean duration/patient of the catheter was 422 days (range 28-1257) in group I; 104 days (range 43-262) in group II; and 415 days (range 62-1280) in group III. There were no catheter related complications in the patients in group I (short bowel syndrome). Of the 11 patients with AIDS (group II) 4 developed catheter related infections (0.32/100 catheter days), and 1 developed a thrombotic occlusion. All 5 catheters were removed (3 for infection). Of the 15 patients with lymphoma or myeloma who had 16 catheters implanted (group III), 1 patient developed 3 infective episodes (0.05/100 catheter days), 1 catheter migrated and 1 occluded. All 3 catheters were removed. Conclusion: Totally implantable infusion systems can safely be used for prolonged periods in immunocompromised patients, including those with AIDS if their life expectancy is reasonable.

AB - Objective: To evaluate the life span and complication rates of totally implantable infusion devices in patients with short bowel syndrome and in immunocompromised patients with AIDS, lymphoma, and myeloma who required long term central venous access. Design: Prospective open study. Setting: University hospital, Italy. Subjects: Group I - 5 patients with short bowel syndrome; group II - 11 patients with AIDS; and group III - 15 patients with lymphoma or multiple myeloma (1 of whom had 2 devices implanted). Main outcome measures: Duration of implantation and incidence of catheter-related complications. Results: The mean duration/patient of the catheter was 422 days (range 28-1257) in group I; 104 days (range 43-262) in group II; and 415 days (range 62-1280) in group III. There were no catheter related complications in the patients in group I (short bowel syndrome). Of the 11 patients with AIDS (group II) 4 developed catheter related infections (0.32/100 catheter days), and 1 developed a thrombotic occlusion. All 5 catheters were removed (3 for infection). Of the 15 patients with lymphoma or myeloma who had 16 catheters implanted (group III), 1 patient developed 3 infective episodes (0.05/100 catheter days), 1 catheter migrated and 1 occluded. All 3 catheters were removed. Conclusion: Totally implantable infusion systems can safely be used for prolonged periods in immunocompromised patients, including those with AIDS if their life expectancy is reasonable.

KW - AIDS patients

KW - cancer patients

KW - catheter related complications

KW - infusion ports

UR - http://www.scopus.com/inward/record.url?scp=0028903908&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028903908&partnerID=8YFLogxK

M3 - Article

C2 - 7772631

AN - SCOPUS:0028903908

VL - 161

SP - 137

EP - 142

JO - European Journal of Surgery, Acta Chirurgica

JF - European Journal of Surgery, Acta Chirurgica

SN - 1102-4151

IS - 2

ER -